Hear­ing loss spe­cial­ists at Fre­quen­cy pin the blame for PhI­Ia flop on tri­al de­sign — but they could­n't stem a freefall in share price

When Fre­quen­cy Ther­a­peu­tics scored $80 mil­lion in cash from Astel­las to jump­start an al­liance, the biotech cau­tious­ly point­ed to Phase I/II da­ta bol­ster­ing hope that they might in­deed have a ground­break­ing re­gen­er­a­tive med­i­cine ap­proach to restor­ing hear­ing, lean­ing on re­search done by Bob Langer and Jeff Karp out of MIT around prog­en­i­tor cell ac­ti­va­tion.

New­ly re­leased Phase IIa re­sults are now keep­ing them away from that lofty goal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER